Report cover image

30-Country IVD Market Atlas, 2025

Publisher Kalorama Information
Published Mar 01, 2025
Length 200 Pages
SKU # KLI19997576

Description

Updated quarterly (four times a year) to reflect market changes

Kalorama Information’s 30-Country IVD Market Atlas, 2025 provides a comprehensive analysis of the in vitro diagnostic (IVD) markets across 30 key countries, including the U.S., China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, and Turkey, among others. This in-depth report delivers detailed market sizing, forecasts for 2029 and 2030, and quarterly updates throughout 2025, ensuring timely insights into the evolving global IVD landscape.

Leveraging over two decades of market research expertise, Kalorama Information presents a country-level approach, offering granular estimates for critical IVD segments, including:
  • Blood Bank Screening - Immunos
  • Coagulation PT/Routine
  • Critical Care (core lab)
  • General Chemistries
  • Hematology
  • Histology
  • Immunoassays – Micro
  • Immunoassays - Non-Micro
  • Microbiology – ID/AST
  • Molecular - Other
  • Molecular Bloodstream/HAI
  • Molecular HIV & Hepatitis
  • Molecular Respiratory
  • POC Critical Care
  • POC Fecal Occult
  • POC Glucose (all)
  • POC Infectious Disease (all)
  • POC Pregnancy & Fertility
  • Other IVD
  • Other POC
The report captures key market drivers, including international developments, regulatory changes, mergers and acquisitions, and new product launches, providing essential intelligence for industry stakeholders. Unlike fragmented country-specific reports, Kalorama’s 30-Country IVD Market Atlas, 2025 consolidates these insights into a single, authoritative resource, aligning with its mission to deliver comprehensive and actionable market intelligence.

Subscribers gain access to the report’s quarterly updates via Kalorama’s Knowledge Center, ensuring they remain informed with the most up-to-date data for strategic decision-making in the dynamic global IVD market.

Table of Contents

200 Pages
    • IVD Market Demand and Growth
    • Scope and Methodology
    • Market Segmentation
    • United States IVD Market Overview
    • IVD News in the United States
    • Germany IVD Market Overview
    • IVD News in Germany
    • China IVD Market Overview
    • IVD News in China
    • Japan IVD Market Overview
    • IVD News in Japan
    • France IVD Market Overview
    • IVD News in France
    • United Kingdom IVD Market Overview
    • IVD News in the United Kingdom
    • Italy IVD Market Overview
    • IVD News in Italy
    • Canada IVD Market Overview
    • IVD News in Canada
    • Spain IVD Market Overview
    • IVD News in Spain
    • Australia IVD Market Overview
    • IVD News in Australia
    • Brazil IVD Market Overview
    • India IVD Market Overview
    • IVD News in India
    • Russia IVD Market Overview
    • The Netherlands IVD Market Overview
    • IVD News in the Netherlands
    • Switzerland IVD Market Overview
    • IVD News in Switzerland
    • Poland IVD Market Overview
    • Turkey IVD Market Overview
    • Mexico IVD Market Overview
    • Sweden IVD Market Overview
    • Belgium IVD Market Overview
    • Austria IVD Market Overview
    • Saudi Arabia IVD Market Overview
    • South Korea IVD Market Overview
    • IVD News in South Korea
    • Egypt IVD Market Overview
    • Romania IVD Market Overview
    • South Africa IVD Market Overview
    • Indonesia IVD Market Overview
    • Chile IVD Market Overview
    • United Arab Emirates IVD Overview
    • IVD News in the United Arab Emirates
    • Vietnam IVD Market Overview
    • Blood Bank Screening (Immunos), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Coagulation PT/INR, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Critical Care (core lab), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • General Chemistries, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Hematology, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Histology, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Immunoassays (Micro), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Immunoassays (Non-Micro), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Microbiology (ID/AST), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Molecular Bloodstream/HAI, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Molecular HIV & Hepatitis, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Molecular Respiratory, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Molecular (Other*), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • POC Critical Care , Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • POC Fecal Occult, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • POC Glucose (all), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • POC Infectious Disease (all), Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • POC Pregnancy & Fertility, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Other IVD, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]
    • Other POC, Global IVD Segment by Leading Countries, Estimated 2024-2029 ($ million) [Australia, Austria, Belgium, Brazil, Canada, Chile, China, Egypt, France, Germany, India, Indonesia, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, Saudi Arabia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, UAE, U.K., U.S., Vietnam]

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us